71. Idiopathic osteonecrosis of the femoral head Clinical trials / Disease details

Clinical trials : 3 / Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 11

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000032412	2016/08/21	27/04/2018	Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head		idiopathic osteonecrosis of the femoral head	Lansoprazole 30mg orally once a day for one year No administration	Sapporo Medical University Hospital	NULL	Complete: follow-up complete	18years-old	75years-old	Male and Female	100	Phase 2	Japan
2	JPRN-UMIN000009610	2012/12/26	26/12/2012	Clinical study for reducing the risk of progress of idiopathic osteonecrosis of the femoral head (ION) by teriparatide treatment		idiopathic osteonecrosis of the femoral head	Teriparatide Acetate Normal treatment	Asahikawa Medical University	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	50	Not selected	Japan
3	NCT03112785 (ClinicalTrials.gov)	March 17, 2011	7/3/2017	Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations	Randomized Comparison Between the Fitmore and the CLS Stem in Patients Operated in One-stage Due to Bilateral Symptomatous Hip Disease	Primary Hip Osteoarthritis;Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease;Bilateral Hip Disease;Surgical Treatment	Device: Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)	Sahlgrenska University Hospital, Sweden	Zimmer Biomet	Active, not recruiting	35 Years	75 Years	All	44	N/A	NULL